Weekly Reports | 10:30 AM
A summary of the highlights from Broker Call Extra updates throughout the week past.
Broker Rating Changes (Post Thursday Last Week)
Upgrade
29METALS LIMITED ((29M)) Upgrade to Buy from Hold by Canaccord Genuity.B/H/S: 0/0/0
Canaccord Genuity maintains a Buy rating for 29Metals with a $0.40 target price following progress on the Capricorn Copper restart and a stronger October at Golden Grove.
Queensland's DETSI has issued preliminary approval for the environmental authority amendment covering a third tailings storage facility, leaving the Federal EPBC process as the final approval required, with the restart definitive feasibility study on track for completion by end-2026.
Ore mined at Golden Grove rose 5% month on month to 156kt against Canaccord's 127kt estimate, the highest monthly volume in more than three years, with throughput equivalent to an annualised 1.6Mtpa.
Canaccord sees additional ore sources driving a turnaround at Golden Grove in 2027 as it emerges from a phase of capital development.
Funding discussions covering streaming, royalty and joint ventures are progressing ahead of a final investment decision, and restarting Capricorn has the potential to more than double annual copper production.
BELLEVUE GOLD LIMITED ((BGL)) Upgrade to Buy from Overweight by Jarden.B/H/S: 0/0/0
Jarden upgrades its rating for Bellevue Gold to Buy from Overweight with an unchanged $1.80 target price following the early closure of the company's hedge book and a balance sheet refinancing.
The remaining 57.5koz of hedges at an average price of $3,061/oz will be retired during the December quarter of 2026 (roughly six months ahead of Jarden's prior schedule) through physical delivery of around 19koz and a pre-tax cash settlement of roughly -$100m for the remaining 38koz, establishing full spot gold exposure from 1 January 2027.
A new three-year, $250m syndicated revolving credit facility replaces the existing $100m Macquarie ((MQG)) facility on improved terms, leaving projected year-end 2026 liquidity at $266m and net debt including leases at $220m.
Jarden retains its net present value-based $1.80 valuation using an unchanged long-term gold price of US$3,300/oz, anticipating a potential share price re-rating as the unhedged producer reverts to net cash within six to nine months despite downside risks from gold prices and mined grade variability.
Downgrade
MAYNE PHARMA GROUP LIMITED ((MYX)) Downgrade to Hold from Buy by Canaccord Genuity.B/H/S: 0/0/0
Canaccord Genuity lowers its rating for Mayne Pharma to Hold from Speculative Buy with its target price increased to $6.40 from $3.65 following the signing of a binding scheme implementation deed with Gedeon Richter.
Unanimously recommended by Mayne Pharma Group's board and supported by shareholders holding 22.14% of the register, the $6.40 per share offer represents a 75% premium to Canaccord's prior valuation and is scheduled to complete in March 2027.
Incorporating the pending $55.5m International business divestment to Evaris in early 2027 and expected convertible note conversion by Rubric Capital in December 2026, Canaccord forecasts normalised EBITDA of $35.3m in FY27 and $32.9m in FY28.
Canaccord's sum-of-the-parts valuation attributes $360.6m to Women's Health, $111.2m to Dermatology, and $132.5m to pro-forma FY27 year-end cash.
Canaccord considers the bid fairly priced to close with limited scope for a competing offer, noting the $0.42 per share trading spread reflects lingering investor scepticism alongside regulatory, integration, and commercial execution risks.
TECHNOLOGY ONE LIMITED ((TNE)) Downgrade to Neutral from Overweight by Jarden.B/H/S: 0/0/0
Jarden downgrades its rating for TechnologyOne to Neutral from Overweight with its target price increased to $32.00 from $31.00 following an FY26 result featuring top-end guidance delivery.
Annual recurring revenue rose 18% to $652.1m and profit before tax climbed 20% to $217.6m at a 32% margin, while UK annual recurring revenue increased 18% to $61m—or 25% in constant currency—to sit -4.3% below consensus amid foreign exchange headwinds and local government reform delays.
Research and development expenditure of $180m exceeded the 20% to 25% revenue target range due to investment in conversational AI products Plus and Guide, while total dividends reached 40.5c per share alongside a record $87m on-market share buyback.
Adopting an equal-weighted valuation combining 28x one-year forward EV/EBITDA and a discounted cash flow model using an 8.74% weighted average cost of capital, Jarden considers the shares fairly valued at current multiples despite reiterated management targets for over $1bn in annual recurring revenue by FY30.
| Order | Company | New Rating | Old Rating | Broker | |
|---|---|---|---|---|---|
| Upgrade | |||||
| 1 | 29METALS LIMITED | Buy | Neutral | Canaccord Genuity | |
| 2 | BELLEVUE GOLD LIMITED | Buy | Buy | Jarden | |
| Downgrade | |||||
| 3 | MAYNE PHARMA GROUP LIMITED | Neutral | Buy | Canaccord Genuity | |
| 4 | TECHNOLOGY ONE LIMITED | Neutral | Buy | Jarden | |
The full story is for FNArena subscribers only. To read the full story plus enjoy a free two-week trial to our service SIGN UP HERE
If you already had your free trial, why not join as a paying subscriber? CLICK HERE
